Table 1 Mean change from baseline in best corrected visual acuity (BCVA) and central subfield thickness (CST) outcomes at Month 12 (M12) and Month 24 (M24) for the treatment-naïve and non-treatment-naïve patient cohorts.
Treatment-naïve | Non-treatment-naïve | |||||
|---|---|---|---|---|---|---|
Baseline | Change from baseline | Baseline | Change from baseline | |||
BCVA (Letters) | M12 (N = 388) | Mean (SD) | 71.4 (12.0) | 2.5 (12.2) | 68.8 (13.7) | 0.2 (10.2) |
95% CI | - | 1.3, 3.8 | - | −1.5, 1.8 | ||
n | 375 | 353 | 166 | 153 | ||
M24 (N = 326) | Mean (SD) | 71.5 (12.4) | 0.7 (12.7) | 69.5 (12.8) | −0.3 (13.0) | |
95% CI | - | −0.7, 2.1 | - | −2.5, 1.9 | ||
n | 326 | 326 | 135 | 135 | ||
CST (µm) | M12 (N = 169) | Mean (SD) | 448.7 (88.7) | −119.1 (116.4) | 419.3 (121.0) | −79.1 (137.6) |
95% CI | - | −130.7, −107.4 | - | −100.2, −58.0 | ||
n | 388 | 386 | 169 | 166 | ||
M24 (N = 135) | Mean (SD) | 447.6 (77.3) | −123.3 (104.3) | 422.5 (117.8) | −91.6 (132.9) | |
95% CI | - | −134.7, −112.0 | - | −114.2, −69.0 | ||
n | 326 | 326 | 135 | 135 | ||
